insiderwall
Menu
SuperinvestorInsider
Olema Pharmaceuticals Inc. OLMA

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, particularly breast cancer. Its lead product candidate, palazestrant (OP-1250), is an oral therapy that acts as both a complete estrogen recept

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees137
TickerOLMA

Statistics

Market Cap$810.4M
Revenue (TTM)$0
Net Income-$162.5M
Net Margin
EPS$-1.87
P/E-5.28
P/S
P/B1.66
EV/EBITDA-1.83
ROE-42.9%
Dividend Yield
Price$9.28

Data: Twelve Data · Revenue = mcap / P/S